慢性血栓栓塞性肺疾病
本文阐述慢性血栓栓塞性肺疾病(CTEPD)的病理为血栓未溶解所致机械阻塞与微血管病变共同增加肺血管阻力,诊断常延迟,需高质量影像确认并制定治疗方案。所有CTEPD患者尤其合并肺动脉高压者应转诊至专家中心行多学科决策,首选评估可手术性,机械治疗(肺动脉内膜剥脱术与球囊肺动脉成形术)症状与生存获益最佳,多模式治疗下3年生存率>90%。
要点
- CTEPD病理为机械阻塞与微血管病变共同增加肺血管阻力。
- 所有CTEPD患者尤其合并肺动脉高压者应转诊专家中心多学科决策。
- 首选评估可手术性,机械治疗症状与生存获益最佳。
核心结论
- CTEPD是多模式可治的疾病,机械治疗可获最佳症状与生存改善,多模式治疗下3年生存率>90%。
主要发现
- 病理为血栓未溶解所致机械阻塞与不同程度微血管病变共同贡献肺血管阻力。
- 诊断常延迟,评估需高质量影像以确认疾病并制定治疗计划。
- 机械治疗(肺动脉内膜剥脱术与球囊肺动脉成形术)症状与生存改善最佳。
- 多模式治疗进展下可实现3年生存率>90%。
关键数值与推荐
- 所有CTEPD患者尤其合并肺动脉高压者应转诊专家中心行多学科团队治疗决策。
- 治疗首要决策为评估可手术性。
临床怎么用
- 对CTEPD患者应尽早转诊专家中心行多学科评估。
- 治疗决策首先评估可手术性,优先考虑机械治疗。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Chronic thromboembolic pulmonary hypertension is a complication of pulmonary embolism and a treatable cause of pulmonary hypertension. The pathology is a unique combination of mechanical obstruction due to failure of clot resolution, and a variable degree of microvascular disease, that both contribute to pulmonary vascular resistance. Accordingly, multiple treatments have been developed to target the disease components. However, accurate diagnosis is often delayed. Evaluation includes high-quality imaging modalities, necessary for disease confirmation and for appropriate treatment planning. All patients with chronic thromboembolic pulmonary disease, and especially those with pulmonary hypertension, should be referred to expert centres for multidisciplinary team decision on treatment. The first decision remains assessment of operability, and the best improvement in symptoms and survival is achieved by the mechanical therapies, pulmonary endarterectomy and balloon pulmonary angioplasty. With the advances in multimodal therapies, excellent outcomes can be achieved with 3-year survival of >90%.
引用
- Kim NH, D'Armini AM, Delcroix M, et al. Chronic thromboembolic pulmonary disease. Eur Respir J. 2024. PMID: 39209473. doi:10.1183/13993003.01294-2024
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。